

Plasma D-Dimer Value Corrected with Some Physiological and Inflammatory Markers (C-Reactive Protein and Ferritin) in Iraqi Patients with COVID-19 Infection

Reem M. Obaid¹, Sanaa Hussein Ali², Zainab Ali Hussein³ and Hadeel Q.A. Habeeb⁴

¹Department of Medical Laboratory Techniques, Al-Farabi University College, Baghdad- Al-Doura, IRAQ.

²Department of Medical Laboratory Techniques, Al-Farabi University College, Baghdad- Al-Doura, IRAQ.

³Department of Medical Laboratory Techniques, Al-Farabi University College, Baghdad- Al-Doura, IRAQ.

⁴Institute of Genetic Engineering and Biotechnology for Postgraduate Studies, Baghdad- Al-Doura, IRAQ.

¹Corresponding Author: reemm24378@gmail.com



www.jrasb.com || Vol. 2 No. 6 (2023): December Issue

Received: 23-12-2023

Revised: 25-12-2023

Accepted: 27-12-2023

ABSTRACT

Since the beginning of the COVID-19 pandemic it has been observed that patients have elevated plasma levels of D-dimer and some inflammatory markers (ferritin, interleukine 6, C-reactive protein (CRP) or fibrinogen). Some studies point to the existence of a certain correlation between those markers and D-dimer. CRP is a protein discovered in the 1930s by Tillett and Francis and is an acute phase reactant. It is a pentameric protein which is synthesized by the liver under the action of cytokine interleukin 6 (IL-6). D-dimers are multiple peptide fragments produced as a result of degradation of crosslinked fibrin, mediated by plasmin. A total of 60 patients were recruited and categorized into :1- group1 (controls), 2- group 2 (COVID-19 patients). 5 ml of blood was obtained from each patient by vein puncture, using 5 ml disposable syringes, then centrifuged at 3000 rpm for 10 minutes to collect the serum. D- dimer, C-reactive protein were measured by using (Roche Diagnostics GmbH, Mannheim, Germany). At the same time, the Ferritin was assessed by using a miniVIDAS analyzer for the fluorescent enzymatic detection of β 2-microglobulin (β 2M) using the technique.

Enzyme Linked Fluorescent Assay (ELFA) (BioMerieux). Our results showed that there was a non- significant difference in the P-values between control and patients males and females. The Mean \pm SE of age in control group was 45.90 ± 3.34 , while the Mean \pm SE of age in patients was 45.35 ± 2.52 . There was a non- significant difference between the two groups, the Mean \pm SE of CRP in control group was 5.04 ± 0.81 , while the Mean \pm SE of CRP in COVID-19 patients was 37.16 ± 3.24 , there was a highly Significant differences between them ($P \leq 0.01$).

The CRP of COVID-19 patients were compared with those of control patients, the results shows significant increased CRP in covid-19 patients group as a comparison with the control group, the findings of the study is similar to Jacob Lentner, etal findings. In response to infections, the liver synthesizes significant quantities of acute-phase proteins (APPs), such as CRP. This acute inflammatory protein is a highly sensitive biomarker for inflammation, tissue damage, and infection. It has been shown that CRP levels are correlated with levels of inflammation. CRP levels can promote phagocytosis and activate the complement system. In other words, CRP binds to microorganisms and promotes their removal through phagocytosis. D-dimers are one of the fragments produced when plasmin cleaves fibrin to break down clots. Our study showed that the serum D-dimer concentrations in patients significantly higher than those in control group which is similar to Mamta Soni, etal, 2020 findings.

Elevated D-dimer levels have emerged as a consistent finding in severely ill COVID-19 patients, Multiple studies have identified an association between higher D-dimer levels and an increased risk of mortality in the COVID-19 patient population.

Ferritin is an iron-storing protein; its serum level reflects the normal iron level and helps the diagnosis of iron deficiency anemia. Circulation ferritin level increases during viral infections and can be a marker of viral replication. Our study showed a significant increase in ferritin level in covid-19 patients group compared to control group, which consider similar to [] results.

Although the exact cause for elevated ferritin in COVID-19 infection is unknown, it could be influenced by cytokine release or cellular damage that results in the leakage of intracellular ferritin. It has been previously shown that ferritin is a direct indicator of cellular damage suggestive of an association between organ damage and ferritin production. This could later cause cell death, known as ferroptosis. It is suggested that inflammation associated with sepsis could alter iron metabolism and deficiency to facilitate the immune system, which could be an early sign of COVID.



Keywords- D-dimer, C-reactive protein, ferritin.

I. INTRODUCTION

Since the beginning of the COVID-19 pandemic it has been observed that patients have elevated plasma levels of D-dimer and some inflammatory markers (ferritin, interleukine 6, C-reactive protein (CRP) or fibrinogen) (Tang *et al.*, 2020 ; Dujardin *et al.*, 2020). Some studies point to the existence of a certain correlation between those markers and D-dimer (Al-Samkari *et al.*,2020).

CRP is a protein discovered in the 1930s by Tillett and Francis and is an acute phase reactant. It is a pentameric protein which is synthesized by the liver under the action of cytokine interleukin 6 (IL-6). A very high level of CRP >50 mg/dL is mostly associated with bacterial infections but elevated levels are also seen in injuries, cardiovascular processes and other inflammatory states. Elevated CRP levels not only suggest a pro-inflammatory state but also can be used as a prognostic marker for the underlying disease processes (Sproston *et al.*, 2018)

D-dimers are multiple peptide fragments produced as a result of degradation of crosslinked fibrin, mediated by plasmin (Adam *et al.*,2009). The presence of D-dimers indicates the production and degradation of crosslinked fibrin, reflecting the coagulation and fibrinolysis processes occurring concomitantly. In healthy subjects, it is measurable in small amounts, because 2–3% of fibrinogen is converted to fibrin and enters the fibrinolytic pathway under normal physiological conditions (Thachil *et al.*, 2017). Any processes that involve production and breakdown of fibrin cause an elevation in D-dimer levels. These include acute venous thromboembolism (VTE), cancer, pregnancy, acute or chronic inflammatory states, acute infections and surgery. As it lacks specificity its role in the current scenario is mainly limited to rule out acute VTE. D-dimer levels vary among patients with confirmed VTE depending on clot burden, timing of measurement, and initiation of treatment (Linkins and Takach, 2017). The body contains iron in the form of ferritin, which is an intracellular protein composed of 24 subunits circling an iron core containing 4000–4500 iron atoms (Domellof *et al.*,2002). Ferritin is an intracellular protein composed of 24 subunits surrounding an iron core containing 4000–4500 iron atoms. Ferritin is a mediator for immune dysregulation, especially in hyper-ferritinemia, with

direct immune suppressive and pro-inflammatory effects that cause cytokine storms (Abbaspour *et al.*, 2014) . The cytokine storm syndrome causes dangerous outcomes in covid-19 disease and the prevalence of the symptoms is depending on the cytokine cloud syndrome (Jin *et al.*, 2020) . Serum ferritin levels are closely linked to the incidence of covid-19 disease (Liu *et al.*, 2020). Manipulation of serum ferritin levels may be used to reduce nutritional iron (Ju and Ha, 2016).

Aim of the study:

To evaluate the value of D- dimer, C- reactive protein and ferritin in COVID- 19 patients.

II. MATERIALS AND METHODS

2.1 Subjects and study design

A total of 60 patients were recruited and categorized into :

- 1- group1 (controls)
- 2- group 2 (COVID-19 patients)

2.2. Methods:

Blood Sample Collection:

The following biochemical investigations have been studied for the estimation of D- dimer, C-reactive protein and ferritin. 5 ml of blood was obtained from each patient by vein puncture, using 5 ml disposable syringes, then centrifuged at 3000 rpm for 10 minutes to collect the serum. D- dimer, C-reactive protein were measured by using (Roche Diagnostics GmbH, Mannheim, Germany). At the same time, the Ferritin was assessed by using a miniVIDAS analyzer for the fluorescent enzymatic detection of β 2-microglobulin (β 2M) using the technique Enzyme Linked Fluorescent Assay (ELFA) (BioMerieux).

2. 3. Statistical Analysis:

The Statistical Analysis System- SAS (2018) program was used to detect the effect of difference factors in study parameters. T-test (Analysis of Variation-ANOVA) was used to significant compare between means in this study.

III. RESULTS

Table 3.1 showed that there was a non-significant difference in the P-values between control and patients males and females.

Table 3.1: Distribution of study samples according to Sex in different Groups

Group	No	Male No. (%)	Female No. (%)	P-value
Control	10	4 (40.00%)	6 (60.00%)	0.184 NS
Patients: COVID-19	40	20	20	1.00 NS

		(50.00%)	(50.00%)	
P-value	---	0.207 NS	0.207 NS	---
NS: Non-Significantly.				

In the table 3.2, The Mean ± SE of age in control group was 45.90 ± 3.34, while the Mean ± SE of age in

patients was 45.35 ± 2.52. There was a non- significant difference between the two groups.

Table 3.2: Comparison in age between different groups

Group	No	Mean ± SE Age (year)
Control	10	45.90 ± 3.34
Patients: COVID-19	40	45.35 ± 2.52
T-test	---	10.758 NS
P-value	---	0.918
NS: Non-Significantly.		

Table 3.3 showed that the Mean ± SE of CRP in control group was 5.04 ±0.81, while the Mean ± SE of

CRP in COVID-19 patients was 37.16 ±3.24, there was a highly Significant differences between them (P<0.01).

Table 3.3: Comparison between difference groups in CRP, D-dimer and Ferritin

Group	Mean ± SE		
	CRP (mg/L)	D-dimer (mg/L)	Ferritin (mg/L)
Control	5.04 ±0.81 b	309.06 ±40.76 b	78.66 ±17.10 b
Patients: COVID-19	37.16 ±3.24 a	572.49 ±40.09 a	451.79 ±38.61 a
T-test	13.159 **	167.27 **	157.38 **
P-value	0.0001	0.0027	0.0001
Means having with the different letters in same column differed significantly. * (P<0.05), ** (P<0.01).			

Significant (P<0.05)* Highly Significant (P<0.01) **NS: Non Significant




Figure 1. Comparison between difference groups in CRP (mg/L)




Figure 2. Comparison between difference groups in D-dimer (mg/L)




Figure 3. Comparison between difference groups in Ferritin (mg/L)

IV. DISCUSSION

C-reactive protein is well established as a marker of systemic inflammation and severe infection. As an acute-phase reactant, CRP binds to phosphocholine in pathogens and membranes of host cells, and acts as an opsonin to enhance phagocytosis and facilitate clearance (Nathaniel R Smilowitz, etal, 2021).

In the current study, the CRP of COVID-19 patients were compared with those of control patients, the results shows significant increased CRP in covid-19 patients group as a compression with the control group, the findings of the study is similar to (Jacob Lentner, etal, 2021).

In response to infections, the liver synthesizes significant quantities of acute-phase proteins (APPs), such as CRP (Khalil R. H., etal). This acute inflammatory protein is a highly sensitive biomarker for inflammation, tissue damage, and infection (Sproston N. R., etal). It has been shown that CRP levels are correlated with levels of inflammation. CRP levels can promote phagocytosis and activate the complement system (Gershov D., Kim S.etal). In other words, CRP binds to microorganisms and promotes their removal through phagocytosis (Povoa P., Pereira J., etal).

D-dimers are one of the fragments produced when plasmin cleaves fibrin to break down clots (Hayroğlu Mİ, etal, 2020). Our study showed that the serum D-dimer concentrations in patients significantly higher than those in control group which is similar to (Mamta Soni, etal, 2020) findings.

Elevated D-dimer levels have emerged as a consistent finding in severely ill COVID-19 patients, Multiple studies have identified an association between higher D-dimer levels and an increased risk of mortality in the COVID-19 patient population (Hayroğlu Mİ, etal, 2020).

Ferritin is an iron-storing protein; its serum level reflects the normal iron level and helps the diagnosis of iron deficiency anemia. Circulation ferritin level increases during viral infections and can be a marker of viral replication (Baraboutis IG, etal, 2020). Our study showed a significant increase in ferritin level in covid-19 patients group compared to control group, which consider similar to [Shilia Jacob Kurian, etal.2023] results.

although the exact cause for elevated ferritin in COVID-19 infection is unknown, it could be influenced by cytokine release or cellular damage that results in the leakage of intracellular ferritin (M. Pujani, etal .2021).

It has been previously shown that ferritin is a direct indicator of cellular damage suggestive of an association between organ damage and ferritin production. This could later cause cell death, known as ferroptosis. It is suggested that inflammation associated with sepsis could alter iron metabolism and deficiency to facilitate the immune system, which could be an early sign of COVID (F.T. Bozkurt, etal 2021).

REFERENCES

- [1] Tang,N.; Bai, H.; Chen, X.; Gong, J. and Sun, D. Li, Z. (2020). Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy.J Thromb Haemost, 18 , pp. 1094-1099.
- [2] Dujardin, R.W.G.; Hilderink, B.N. ; Haksteen, W.E. ; Middeldorp, S. Vlaar, Thachil, A.P.J. J. *et al.* (2020). Biomarkers for the prediction of venous thromboembolism in critically ill COVID-19 patients. *Thromb Res*, 196 , pp. 308-312.
- [3] Al-Samkari, H.; Karp Leaf, R.S.; Dzik, W.H. ; Carlson, J.C.T.; Fogerty, A.E. ; Waheed, A. *et al.* (2020). COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. *Blood*. 136 , pp. 489-500.
- [4] Sproston, N.R.; Ashworth, J.J. Apr. (2018). Role of C-reactive protein at sites of inflammation and infection. *Front Immunol*. 13(9):754.
- [5] Adam, S.S.; Key, N.S.; Greenberg, C.S. (2009). D-Dimer antigen: current concepts and future prospects. *Blood. J Am Soc Hematol*. 26;113(13):2878–2887.
- [6] Thachil, J., Lippi, G.; Favaloro, E.J. (2017). D-Dimer testing: laboratory aspects and current issues. In: *Hemostasis and Thrombosis*. New York, NY: Humana Press . p. 91–104.
- [7] Linkins LA, Takach Lapner S. Review of D-dimer testing: good, Bad, and Ugly. *Int J Lab Hematol*. 2017 May;39:98–103.
- [8] Domellof M., Dewey K.G., Lonnerdal B., Cohen R.J., Hernell O. The diagnostic criteria for iron deficiency in infants should be reevaluated. *J. Nutr*. 2002;132(12):3680–3686.
- [9] Abbaspour N., Hurrell R., Kelishadi R. Review on iron and its importance for human health. *J. Res. Med. Sci*. 2014;19(2):164.
- [10] Jin X., Lian J.S., Hu J.H., Gao J., Zheng L., Zhang Y.M., Yang Y. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. *Gut*. 2020;69(6):1002–1009.
- [11] Liu T., Zhang J., Yang Y., Ma H., Li Z., Zhang J., Yi J. The role of interleukin-6 in monitoring severe case of coronavirus disease 2019. *EMBO Mol. Med*. 2020;12(7)
- [12] Ju S.Y., Ha A.W. Dietary factors associated with high serum ferritin levels in postmenopausal women with the Fifth Korea National Health and Nutrition Examination Survey (KNHANES V), 2010–2012. *Nutrit. Res. Pract*. 2016;10(1):81.
- [13] Khalil R. H., Al-Humadi N. Types of acute phase reactants and their importance in vaccination. *Biomedical Reports*. 2020;12(4):143–152. doi: 10.3892/br.2020.1276.
- [14] Sproston N. R., Ashworth J. J. Role of C-reactive protein at sites of inflammation and infection. *Frontiers*

- in *Immunology*. 2018;9:p. 754.
doi: 10.3389/fimmu.2018.00754.
- [15] Gershov D., Kim S., Brot N., Elkon K. B. C-reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response. *Journal of Experimental Medicine*. 2000;192(9):1353–1364.
doi: 10.1084/jem.192.9.1353.
- [16] Pova P., Pereira J., Coelho L. *C-Reactive Protein: New Research*. 2009. C-reactive protein: structure, synthesis and function; pp. 307–324.
- [17] Nathaniel R Smilowitz, Dennis Kunichoff, Michael Garshick, Binita Shah, Michael Pillinger, Judith S Hochman, Jeffrey S Berger. C-reactive protein and clinical outcomes in patients with COVID-19. *European Heart Journal*, Volume 42, Issue 23, 14 June 2021, Pages 2270–2279,
- [18] Jacob Lentner , Taylor Adams , Valene Knutson , Sarah Zeien , Hassan Abbas , Ryan Moosavi , Chris Manuel , Thomas Wallace , Adam Harmon , Richard Waters , Samuel Ledford , Rajakrishnan Vijayakrishnan , Nikhil Jagan , Nezar Falluji , Michael DelCore , Curt Bay and Sunny Jhamnani. C-reactive protein levels associated with COVID-19 outcomes in the United States, *Journal of Osteopathic Medicine*, 2021
- [19] Hayiroğlu Mİ, Çınar T, Tekkeşin Aİ. Fibrinogen and D-dimer variances and anticoagulation recommendations in Covid-19: current literature review. *Rev Assoc Méd Bras*. 2020;66(6):842-848. Epub July 20, 2020.
- [20] Shilia Jacob Kurian ^a, Sara Poikayil Mathews , Abin Paul ^a, Subeesh K. Viswam , Shivashankara Kaniyoor Nagri , Sonal Sekhar Miraj, Shubhada Karanth. Association of serum ferritin with severity and clinical outcome in COVID-19 patients: An observational study in a tertiary healthcare facility. *Clinical Epidemiology and Global Health*. Vol.21, 2023, 101295
- [21] Baraboutis IG, Gargalianos P, Aggelonidou E, Adraktas A. Initial real-life experience from a designated COVID-19 Centre in Athens, Greece: a proposed therapeutic algorithm. *SN Compr Clin Med*. 2020.
- [22] M. Pujani, S. Raychaudhuri, M. Singh, *et al*. An analysis of hematological, coagulation and biochemical markers in COVID-19 disease and their association with clinical severity and mortality: an Indian outlook *Am J Blood Res*, 11 (6) (2021), p. 580
- [23] F.T. Bozkurt, M. Tercan, G. Patmano, *et al*. Can ferritin levels predict the severity of illness in patients with COVID-19? *Cureus*, 13 (1) (2021)
- [24] SAS. 2018. *Statistical Analysis System, User's Guide*. Statistical. Version 9.6th ed. SAS. Inst. Inc. Cary. N.C. USA.